Project HOPE
Executive Summary
Responding to comments made by Rep. Stark (D-Calif.) at a June 11 hearing, Project HOPE Deputy Director Marc Berk, PhD, said in a June 17 letter that the think-tank's analysis of Stark's Medicare outpatient drug coverage bill (HR 2500) "indicates that we agree about the cost of the bill, but our estimates suggest that many more people would receive benefits under your bill than you estimate." Berk said: "I would think you would be pleased with this result, but instead you elected to criticize our organization before even reading our findings." Stark dismissed the Project HOPE study, implying the group was a "shill" for PMA.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth